S&P 500
7,623.68
-39.75
-0.52%
Dow
52,215.16
-652.82
-1.23%
Nasdaq
25,955.34
-53.52
-0.21%
NYSE Composite
24,126.24
-149.29
-0.61%
Russell 2000
2,776.99
-7.03
-0.25%
VIX
19.72
+0.69
+3.63%
CORT · Corcept Therapeutics Incorporated
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Corcept Therapeutics Inc (CORT)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$85.94
-21.61
(-20.09%)
● At close: October 23 at 4:00:00 PM EDT
$85.86
+0.00
(+0.00%)
After-Hours:
4:00:39 PM EDT
DAY'S RANGE
$85.94
$84.23
$105.06
52-WEEK RANGE
$85.94
$28.66
$126.38
What's happening
- CORT is down 20.09% today, trading at $85.94. — Live quote
- Volume today (160,507) is well below its 3-month average of 1,173,500. (Finnhub fundamentals)
- Reports earnings on 2026-11-04, 12 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.36 actual vs. $0.01 estimated (+6958.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 7
Hold 1
Sell 0
Strong sell 1
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CORT
+234.14%
vs S&P 500
+220.77%
1-YEAR RETURN
CORT
+54.24%
vs S&P 500
+39.07%
6-MONTH RETURN
CORT
+151.91%
3-MONTH RETURN
CORT
+27.95%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.36
Est. $0.01
BEAT +6958.8%
2026-04-26 (Q1 2026)
$-0.30
Est. $-0.10
MISS -204.3%
2026-01-26 (Q4 2025)
$0.20
Est. $0.31
MISS -34.6%
2025-10-26 (Q3 2025)
$0.16
Est. $0.14
BEAT +16.2%
Valuation Measures & Ratios
Enterprise Value4$12.30B
Forward P/E533.32
PEG Ratio6—
Price / Sales (TTM1)14.94
Price / Book713.23
EV4 / Revenue14.81
EV4 / EBITDA1456.88
Profit Margin6.64%
Operating Margin0.77%
Return on Equity (ROE8)8.41%
Return on Assets (ROA9)6.56%
Avg Volume (3M)1,173,500
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $10.37B | $4.27B | $1.28B | $1.11B | $1.73B |
| P/E | 157.07 | 97.86 | 10.43 | 8.04 | 13.17 |
| Price/Sales | 12.60 | 5.89 | 1.72 | 1.59 | 2.65 |
| Price/Book | 14.70 | 6.69 | 2.02 | 1.75 | 2.53 |
| EV/Revenue | 12.47 | 5.74 | 1.55 | 1.45 | 2.52 |
| EV/EBITDA | 337.01 | -530.88 | 13.09 | — | — |
| ROE | 9.36% | 6.83% | 19.40% | 21.77% | 19.17% |
| ROA | 7.43% | 5.35% | 14.88% | 17.26% | 15.48% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short8,540,393
Change from Prior Settlement-8.67%
% of Float—
Days to Cover (Short Ratio)3.57
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 31.7% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +54.2%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is 6.6%. Finnhub fundamentals ↗
- Trailing P/E is 224.9, a high price relative to reported earnings. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CORT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $256.1M | $164.9M | $207.6M | $194.4M | $157.2M | $182.5M | $163.8M | $146.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $41.3M | -$49.6M | $10.2M | $26.7M | $3.4M | $46.6M | $35.6M | $29.5M |
| Net income | $43.0M | -$31.8M | $19.7M | $35.1M | $20.5M | $47.2M | $35.5M | $27.8M |
| EPS (diluted) | $0.36 | $-0.30 | $0.16 | $0.29 | $0.17 | $0.41 | $0.32 | $0.25 |
| EPS (basic) | $0.40 | $-0.30 | $0.19 | $0.33 | $0.19 | $0.45 | $0.34 | $0.27 |
| Operating margin | $16 | -$30 | $5 | $14 | $2 | $26 | $22 | $20 |
| Net margin | $17 | -$19 | $9 | $18 | $13 | $26 | $22 | $19 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $888.7M | $814.9M | $836.7M | $823.6M | $801.7M | $846.5M | $840.6M | $784.3M |
| Total liabilities | $182.9M | $176.9M | $188.8M | $191.7M | $165.9M | $163.2M | $161.0M | $145.4M |
| Stockholders' equity | $705.8M | $638.0M | $647.8M | $631.9M | $635.8M | $683.3M | $679.6M | $638.8M |
| Total current assets | $439.7M | $426.0M | $485.5M | $541.1M | $443.1M | $438.5M | $471.6M | $467.0M |
| Total current liabilities | $153.8M | $149.2M | $166.1M | $172.3M | $144.7M | $143.1M | $140.8M | $126.2M |
| Cash & equivalents | $111.0M | $108.7M | $120.5M | $125.1M | $102.7M | $89.8M | $127.7M | $137.3M |
| Marketable securities (current) | $197.2M | $229.4M | $251.7M | $296.5M | $239.5M | $232.9M | $255.7M | $243.0M |
| Accounts receivable | $76.9M | $39.1M | $59.8M | $69.6M | $64.6M | $61.8M | $54.0M | $59.7M |
| Inventory | $13.2M | $12.9M | $12.9M | $12.3M | $12.3M | $14.4M | $12.4M | $8.1M |
| Other current assets | $8.4M | $6.4M | $7.1M | $6.0M | $7.5M | $24.9M | $6.1M | $4.6M |
| Marketable securities (non-current) | $236.5M | $177.3M | $160.3M | $102.6M | $172.8M | $248.0M | $219.8M | $167.3M |
| Property, plant & equipment | $5.1M | $3.2M | $1.9M | $2.1M | $2.3M | $2.5M | $2.7M | $2.9M |
| Other non-current assets | $2.9M | $5.2M | $5.2M | $8.0M | $8.3M | $6.6M | $6.6M | $7.0M |
| Accounts payable | $14.9M | $33.3M | $40.4M | $34.4M | $23.5M | $27.9M | $15.4M | $18.6M |
| Accrued liabilities | $115.3M | $80.2M | $90.6M | $108.4M | $91.1M | $88.9M | $90.7M | $79.5M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $142.0K | — | $140.0K | $139.0K | $138.0K | — | $136.0K | $135.0K |
| Retained earnings | $654.6M | $611.6M | $643.4M | $619.1M | $599.4M | $564.3M | $543.7M | $513.0M |
| Accumulated other comprehensive income (loss) | $436.0K | $918.0K | $2.3M | $2.3M | $2.3M | $692.0K | -$217.0K | $1.6M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $33.5M | -$16.8M | $38.4M | $54.5M | $44.3M | $4.8M | $60.1M | $73.3M |
| Investing cash flow | -$29.2M | $4.5M | -$11.8M | $14.6M | $70.1M | -$3.2M | -$64.4M | -$44.0M |
| Financing cash flow | -$2.0M | $760.0K | -$31.2M | -$46.4M | -$102.9M | -$39.8M | -$4.6M | -$21.1M |
| Free cash flow | $31.0M | -$17.0M | $38.4M | $54.5M | $44.2M | $4.7M | $59.9M | $71.7M |
| Capital expenditures | $2.5M | $201.0K | $50.0K | $0 | $57.0K | $104.0K | $121.0K | $1.6M |
| Depreciation & amortization | $863.0K | $598.0K | $289.0K | -$71.0K | $469.0K | $462.0K | $281.0K | $318.0K |
| Share-based compensation | $29.4M | $23.0M | $20.8M | $22.9M | $19.0M | $21.8M | $16.8M | $16.1M |
| Deferred income taxes | $2.9M | -$13.1M | -$15.2M | $9.1M | -$17.8M | -$13.7M | -$3.9M | -$15.2M |
| Change in accounts receivable | $37.8M | -$20.7M | -$9.8M | $5.1M | $2.7M | $7.8M | -$5.7M | $5.9M |
| Change in inventory | $4.3M | $3.3M | -$483.0K | $3.9M | $4.6M | -$605.0K | $78.0K | -$1.1M |
| Change in accounts payable | -$18.2M | -$7.6M | $6.0M | $10.9M | -$4.4M | $12.6M | -$3.1M | -$649.0K |
| Purchases of investments | $89.0M | $52.3M | $143.8M | $37.4M | $23.3M | $115.1M | $144.6M | $223.1M |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Share repurchases | $0 | $0 | $0 | $42.5M | $103.0M | $27.4M | $0 | $11.7M |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $11.5M | $5.8M | $36.5M | $8.2M | $12.4M | $15.8M | $7.0M | $11.7M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M |
| Net income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M |
| EPS (diluted) | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
| EPS (basic) | $0.95 | $1.35 | $1.02 | $0.95 | $0.97 |
| Operating margin | $6 | $20 | $22 | $28 | $34 |
| Net margin | $13 | $21 | $22 | $25 | $31 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $836.7M | $840.6M | $621.5M | $583.4M | $423.8M |
| Total liabilities | $188.8M | $161.0M | $114.8M | $81.6M | $48.0M |
| Stockholders' equity | $647.8M | $679.6M | $506.7M | $501.8M | $375.8M |
| Total current assets | $485.5M | $471.6M | $458.6M | $499.3M | $266.5M |
| Total current liabilities | $166.1M | $140.8M | $104.5M | $72.5M | $47.5M |
| Cash & equivalents | $120.5M | $127.7M | $135.6M | $66.3M | $77.6M |
| Marketable securities (current) | $251.7M | $255.7M | $232.7M | $365.3M | — |
| Accounts receivable | $59.8M | $54.0M | $41.1M | $31.1M | $27.6M |
| Inventory | $12.9M | $12.4M | $7.7M | $6.1M | $5.0M |
| Other current assets | $7.1M | $6.1M | $5.9M | — | — |
| Marketable securities (non-current) | $160.3M | $219.8M | $57.2M | $4.9M | — |
| Property, plant & equipment | $1.9M | $2.7M | $195.0K | $633.0K | $1.0M |
| Other non-current assets | $5.2M | $6.6M | $6.5M | $5.1M | $3.1M |
| Accounts payable | $40.4M | $15.4M | $17.4M | $12.0M | $6.9M |
| Accrued liabilities | $90.6M | $90.7M | $51.6M | $30.8M | $27.7M |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $140.0K | $136.0K | — | $131.0K | $127.0K |
| Retained earnings | $643.4M | $543.7M | $402.5M | $296.4M | $195.0M |
| Accumulated other comprehensive income (loss) | $2.3M | -$217.0K | $609.0K | -$869.0K | -$227.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $142.0M | $198.3M | $126.7M | $120.3M | $167.9M |
| Investing cash flow | $69.8M | -$177.6M | $90.9M | -$114.3M | $136.1M |
| Financing cash flow | -$220.4M | -$28.3M | -$148.7M | -$17.3M | -$302.6M |
| Free cash flow | $141.8M | $196.1M | $126.5M | $119.9M | $167.4M |
| Capital expenditures | $211.0K | $2.2M | $139.0K | $413.0K | $469.0K |
| Depreciation & amortization | $1.1M | $795.0K | $1.0M | $1.3M | $1.1M |
| Share-based compensation | $84.5M | $61.4M | $48.9M | $42.4M | $42.9M |
| Deferred income taxes | -$37.5M | -$40.2M | -$29.5M | -$33.9M | $4.3M |
| Change in accounts receivable | $5.8M | $12.9M | $10.1M | $3.4M | $1.4M |
| Change in inventory | $7.5M | -$305.0K | -$1.3M | -$1.2M | -$3.4M |
| Change in accounts payable | $25.1M | -$2.0M | $5.4M | $4.8M | -$3.6M |
| Purchases of investments | $319.6M | $588.3M | $328.7M | $355.1M | $312.8M |
| Sales/maturities of investments | — | — | $0 | $0 | $50.5M |
| Share repurchases | $172.9M | $15.7M | $0 | $0 | — |
| Debt repaid | — | — | — | — | — |
| Tax withholding on stock comp | $72.9M | $22.3M | $9.1M | $21.7M | $22.8M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CORT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-08-10 to 2026-10-15
Recent transactions
- Insiders have net sold 359,203 shares over the last 182 days, across 0 purchases and 43 sales.
- Most recent: WILSON JAMES N (Reporting person) — Open market sale of 6,654 shares on 2026-10-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)359,203 sh(43 txns)
Net Shares-359,203
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| WILSON JAMES N | Reporting person | Open market sale | 2026-10-15 | 6,654 |
| Vieira Roberto Wandenkolk | President, Oncology | Option exercise | 2026-10-02 | 8,333 |
| Lyon Joseph Douglas | See Remarks | Option exercise | 2026-10-02 | 3,357 |
| Maduck Sean | See Remarks | Option exercise | 2026-10-02 | 24,587 |
| Robb Gary Charles | Chief Business Officer | Gift | 2026-09-24 | 17,100 |
| Mokari Atabak | Chief Financial Officer | Tax withholding | 2026-09-02 | 102 |
| Guyer William | Chief Development Officer | Grant / award | 2026-09-01 | 164 |
| Park Kimberly | Reporting person | Option exercise | 2026-08-26 | 30,000 |
| MAHONEY DAVID L | Reporting person | Open market sale | 2026-08-18 | 4,984 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-15 | WILSON JAMES N | Reporting person | Open market sale | 6,654 | $114.48 |
| 2026-10-15 | WILSON JAMES N | Reporting person | Open market sale | 3,046 | $115.39 |
| 2026-10-15 | WILSON JAMES N | Reporting person | Open market sale | 300 | $116.30 |
| 2026-10-02 | Vieira Roberto Wandenkolk | President, Oncology | Option exercise | 8,333 | $21.63 |
| 2026-10-02 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 1,100 | $114.52 |
| 2026-10-02 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 2,086 | $115.73 |
| 2026-10-02 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 5,147 | $116.58 |
| 2026-10-02 | Lyon Joseph Douglas | See Remarks | Option exercise | 3,357 | $13.56 |
| 2026-10-02 | Lyon Joseph Douglas | See Remarks | Option exercise | 5,833 | $19.26 |
| 2026-10-02 | Lyon Joseph Douglas | See Remarks | Open market sale | 4,446 | $115.70 |
| 2026-10-02 | Lyon Joseph Douglas | See Remarks | Open market sale | 4,744 | $116.54 |
| 2026-10-02 | Maduck Sean | See Remarks | Option exercise | 24,587 | $8.27 |
| 2026-10-02 | Maduck Sean | See Remarks | Open market sale | 15,843 | $116.12 |
| 2026-10-02 | Maduck Sean | See Remarks | Open market sale | 8,744 | $116.55 |
| 2026-10-01 | Lyon Joseph Douglas | See Remarks | Option exercise | 810 | $13.56 |
| 2026-10-01 | Lyon Joseph Douglas | See Remarks | Open market sale | 810 | $115.40 |
| 2026-10-01 | Maduck Sean | See Remarks | Option exercise | 413 | $8.27 |
| 2026-10-01 | Maduck Sean | See Remarks | Open market sale | 413 | $115.54 |
| 2026-09-24 | Robb Gary Charles | Chief Business Officer | Gift | 17,100 | $0.00 |
| 2026-09-24 | Robb Gary Charles | Chief Business Officer | Gift | 5,000 | $0.00 |
| 2026-09-24 | Robb Gary Charles | Chief Business Officer | Gift | 5,000 | $0.00 |
| 2026-09-17 | Robb Gary Charles | Chief Business Officer | Option exercise | 17,493 | $8.27 |
| 2026-09-16 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 296 | $100.82 |
| 2026-09-15 | WILSON JAMES N | Reporting person | Open market sale | 6,800 | $110.27 |
| 2026-09-15 | WILSON JAMES N | Reporting person | Open market sale | 400 | $110.84 |
| 2026-09-15 | WILSON JAMES N | Reporting person | Open market sale | 2,800 | $111.70 |
| 2026-09-14 | Lyon Joseph Douglas | See Remarks | Option exercise | 2,596 | $11.35 |
| 2026-09-14 | Lyon Joseph Douglas | See Remarks | Option exercise | 7,404 | $13.56 |
| 2026-09-14 | Lyon Joseph Douglas | See Remarks | Open market sale | 7,812 | $113.32 |
| 2026-09-14 | Lyon Joseph Douglas | See Remarks | Open market sale | 2,188 | $114.12 |
| 2026-09-02 | Maduck Sean | See Remarks | Tax withholding | 117 | $113.38 |
| 2026-09-02 | Mokari Atabak | Chief Financial Officer | Tax withholding | 102 | $113.38 |
| 2026-09-02 | Robb Gary Charles | Chief Business Officer | Tax withholding | 91 | $113.38 |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Tax withholding | 102 | $113.38 |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Option exercise | 58,333 | $21.63 |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 23,600 | $109.35 |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 23,770 | $110.70 |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 1,537 | $111.37 |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 974 | $112.40 |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 1,606 | $113.72 |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 5,621 | $114.58 |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Open market sale | 1,225 | $115.44 |
| 2026-09-02 | Lyon Joseph Douglas | See Remarks | Tax withholding | 72 | $113.38 |
| 2026-09-01 | Guyer William | Chief Development Officer | Grant / award | 164 | $113.38 |
| 2026-09-01 | Guyer William | Chief Development Officer | Grant / award | 164 | $0.00 |
| 2026-09-01 | Maduck Sean | See Remarks | Option exercise | 25,000 | $8.27 |
| 2026-09-01 | Maduck Sean | See Remarks | Open market sale | 11,730 | $113.94 |
| 2026-09-01 | Maduck Sean | See Remarks | Open market sale | 10,989 | $114.71 |
| 2026-09-01 | Maduck Sean | See Remarks | Open market sale | 2,281 | $115.61 |
| 2026-09-01 | Maduck Sean | See Remarks | Grant / award | 150 | $113.38 |
| 2026-09-01 | Maduck Sean | See Remarks | Grant / award | 150 | $0.00 |
| 2026-09-01 | Mokari Atabak | Chief Financial Officer | Grant / award | 138 | $113.38 |
| 2026-09-01 | Mokari Atabak | Chief Financial Officer | Grant / award | 138 | $0.00 |
| 2026-09-01 | Robb Gary Charles | Chief Business Officer | Grant / award | 164 | $113.38 |
| 2026-09-01 | Robb Gary Charles | Chief Business Officer | Grant / award | 164 | $0.00 |
| 2026-09-01 | Vieira Roberto Wandenkolk | President, Oncology | Grant / award | 138 | $113.38 |
| 2026-09-01 | Vieira Roberto Wandenkolk | President, Oncology | Grant / award | 138 | $0.00 |
| 2026-09-01 | Lyon Joseph Douglas | See Remarks | Grant / award | 130 | $113.38 |
| 2026-09-01 | Lyon Joseph Douglas | See Remarks | Grant / award | 130 | $0.00 |
| 2026-08-26 | Park Kimberly | Reporting person | Option exercise | 30,000 | $13.49 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-23 19:03 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 4 | 2026-10-15 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-02 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-23 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
Recent news
Headlines about CORT (Corcept Therapeutics Incorporated). Links open the publisher — we don’t host full articles.
-
Genmab rises, Corcept falls on late-stage antibody-conjugate data for ovarian cancer
Seeking Alpha · 2026-10-23 -
$CORT stock is down 20% today. Here's what we see in our data.
Quiver Quantitative · 2026-10-23 -
Genmab stock surges 9% following positive phase 3 ovarian cancer trial results
Yahoo · 2026-10-23 -
Why is Corcept Therapeutics stock tumbling today?
Investing.com · 2026-10-23 -
CORT May 2027 155.000 put (CORT270521P00155000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-23 -
CORT Nov 2026 140.000 call (CORT261120C00140000) stock price, news, quote and history
Yahoo Finance Singapore · 2026-10-22 -
2 cash-producing stocks to research further and 1 we find risky
Yahoo · 2026-10-22 -
WULF,CORT,TNL,SBSW,AFCG,TARS,NSP,LBTYK,CRM | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-22
No headlines in this category right now — try “All”.